NASDAQ
Barinthus Biotherapeutics plc (BRNS) has a free cash flow growth of 19.79% as of Friday, May 29, 2026. This represents a 158.07% increase compared to its 12-month average of -34.08%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.